Stock fact sheet · data as of

Omada Health (OMDA): fair value, margin of safety and Wheel Score

Healthcare · Medical - Healthcare Information Services · United States · High Growth

Close18.67
GLS fair value4.097 of 9 models
Margin of safety-357%price above fair value
Wheel Score52Fairout of 100
Health7/9Piotroski F-score
Moat5.0/10GLS 10-year score
Market cap$1.1B1.6M shares a day
Implied vol.74%near-the-money, 20-60 d
P/E258.8EPS 0.07
Dividend yieldnone
Beta2.02moves more than the market
Next earnings5 Nov 2026in 20 days (after the close)

Is OMDA undervalued?

OMDA closed at 18.67 on 16 Oct 2026, more than 30% above the GLS average fair value of 4.09. Only 0 of the 7 models that produced a value sit above the price. By our models the shares are priced well beyond what the filed earnings, cash flow and book value support; the Sunday Scan drops names like this at the "below fair value" rule.

There is a wide gap between EPV (0.8014) and 10 Cap (7.72). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.

The nightly engine files OMDA under High Growth: revenue and earnings growing fast enough that the growth-based models carry the valuation.

Nine valuation models for OMDA

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number2.62-86%The most a defensive investor pays for the earnings and book value per share
Graham Growth4.13-78%Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields
Lynch1.80-90%EPS × the earnings growth rate (PEG of 1), growth capped at 25%
GLS Growth4.42-76%EPS compounded ten years at the blended growth rate, discounted back at 15% a year
10 Cap7.72-59%Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%
Payback Time7.14-62%Eight years of compounded free cash flow: the price at which the business pays for itself
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV0.8014-96%Earnings power value: current EPS capitalised at 9% with no growth
Zombie (liquidation)3.22-83%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target25.88+39%Analysts' average 12-month price target. Not in the average

Quality and financial health

Omada Health scores 7 of 9 on the Piotroski F-score, the nine yes/no tests of profitability, leverage and efficiency on the latest annual accounts - a strong reading that passes the Sunday Scan's "6 or more" rule with room to spare. On durability OMDA scores 5.0/10 on the GLS Moat - a middle reading; the Scorecard on the Quote page's Financials tab shows which ten-year lines are steady and which are not.

Returns on capital are thin or negative - ROIC -5.6%, ROE -5.6%, ROA -4.2% - with debt at 0.00 times equity and a free-cash-flow yield of 2.0%.

Omada Health pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Service 89%, Hardware 12% (quarter Q2 FY2026).

Institutional ownership scores 10/10, insider activity 2/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score7 / 9ROIC-5.6%
GLS Moat5.0 / 10ROE-5.6%
Debt / equity0.00ROA-4.2%
Free-cash-flow yield2.0%Payout ratio0%
Institutions10 / 10Insiders · Congress2 · 5 / 10

Wheel Score 52: Fair

A Wheel Score of 52 puts Omada Health in the Fair band - below the 70 the Sunday Scan requires. Value 0/25, Health 16/20, Moat 8/15, Premium 16/20 and Stability 13/20; the weakest part is Value (0/25).

Implied volatility is 74% on the near-the-money contracts 20-60 days out - above the 60% ceiling of the sweet spot. Premiums are large, but the Wheel Score tapers the Premium points (16 of 20) because volatility this high usually comes with a reason. Chain open interest is 19,005 contracts across all expiries - enough for the wheel at normal size.

Volume runs at 1.6M shares a day on a market cap of $1.1B, with a beta of 2.02 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 13 of 20.

PartPointsFrom
Value0 / 25-357% margin of safety
Health16 / 20Piotroski 7/9
Moat8 / 15moat 5.0/10
Premium16 / 20implied volatility 74%
Stability13 / 201.6M shares/day, $1.1B cap, beta 2.02

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 5 Nov 2026 (after the close), 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Healthcare Information Services

The 12 companies below are the closest to Omada Health by market cap within the Medical - Healthcare Information Services industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
GDRX
GoodRx Holdings, Inc.
3.513.44-2%62Fair$1.2B
TDOC
Teladoc Health, Inc.
5.8121.97+74%45Weak$1.1B
HSTM
HealthStream, Inc.
33.7523.38-44%56Fair$1.0B
CERT
Certara, Inc.
9.668.34-16%45Weak$1.5B
MDRX
Veradigm Inc.
5.00--37No options$851M
OMCL
Omnicell, Inc.
35.9523.57-52%53Fair$1.6B
PHR
Phreesia, Inc.
10.6314.46+26%68Good$657M
SOPH
SOPHiA GENETICS S.A.
7.06--45Weak$601M
EVH
Evolent Health, Inc.
4.874.93+1%45Weak$548M
PRVA
Privia Health Group, Inc.
21.6742.94+50%45Weak$2.8B
NRC
NRC Health
21.118.64-144%47Weak$467M
CTEV
Claritev Corporation
23.86120.21+80%45Weak$404M

⚖ Compare OMDA with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about OMDA

Is OMDA undervalued right now?

No: at 18.67 the stock trades 357% above the GLS average fair value of 4.09 (data as of 16 Oct 2026), well beyond what trailing earnings, cash flow and book value support.

What is the Wheel Score of OMDA and what does it mean?

OMDA scores 52 out of 100 (Fair). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.

What is the GLS fair value for OMDA?

4.09 per share as of 16 Oct 2026 - the simple average of the 7 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Omada Health report earnings next?

The next earnings report is due on 5 Nov 2026 (after the close), 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does OMDA have listed options, and how liquid are they?

Yes. The nightly snapshot found 170 listed contracts with 19,005 open interest across all expiries and implied volatility of 74% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.